Clinical Trial: Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma

U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07521657) titled 'Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma' on April 03.

Brief Summary: This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with recurrent sporadic glioblastoma (GBM) harboring NF1 alterations (Cohort 1); participants with NF1 with a newly diagnosed GBM (Cohort 2); mirdametinib alone in other NF1-associated High-Grade Gliomas (Cohort 3).

Study Start Date: Aug. 01, 2026

Study Type: INTERVENTIONAL

Condition: Neurofibromatosis 1 (NF1)

Intervention: COMBINATION_PRODUCT: mirdametinib with r...